Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma

Journal of Neuro-Oncology

Volumn 126, Issue 3, 2016, Pages 385-393

  Dasgupta, Tina ^a   Olow, Aleksandra K ^b   Yang, Xiaodong ^b   Hashizume, Rintaro ^c   Nicolaides, Theodore P ^b   Tom, Maxwell ^b   Aoki, Yasuyuki ^b   Berger, Mitchel S ^b   Weiss, William A ^b,d   Stalpers, Lukas J A ^e   Prados, Michael ^b   David James, C ^c   Mueller, Sabine ^b,d   Haas Kogan, Daphne A ^b  

^a Valley Radiotherapy Associates   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

BRAF V600E; High grade gliomas; Radiotherapy; Targeted inhibitors

Indexed keywords

B RAF KINASE; BETA GALACTOSIDASE; CASPASE 3; GAMMA HISTONE H2AX; GLUTAMIC ACID; HISTONE H2AX; KI 67 ANTIGEN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROTEIN P21; UNCLASSIFIED DRUG; VALINE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAF GENE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CHEMORADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; RADIOSENSITIZATION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER GRADING; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; GAMMA RADIATION; GENETICS; MORTALITY; MUTATION; NUDE MOUSE; PATHOLOGY; SURVIVAL RATE; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHEMORADIOTHERAPY; GAMMA RAYS; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; MICE; MICE, NUDE; MUTATION; NEOPLASM GRADING; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956638735     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1939-2     Document Type: Article

References (34)

1. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
2. Bamford S et al (2004) The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 91(2):355–358
3. Basto D et al (2005) Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 109(2):207–210
4. Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108(6):467–470
5. Myung JK et al (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. Transl Oncol 5(6):430–436
6. Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405
7. Schiffman JD et al (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512–519
8. Lyustikman Y et al (2008) Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia 10(5):501–510
9. Horbinski C et al (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neurooncology 14(6):777–789
10. Kasid U, Dritschilo A (2003) RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22(37):5876–5884
11. Weidhaas JB et al (2006) A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Res 66(21):10434–10438
12. Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
13. Hauschild A et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365
14. Long GV et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095
15. Dasgupta T et al. (2013) Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas. Investig New Drugs 31(5):1136–1141
16. Sambade MJ et al (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98(3):394–399
17. Michaud K et al (2010) Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70(8):3228–3238
18. Franken NA et al (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5):2315–2319
19. Debacq-Chainiaux F et al (2009) Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4(12):1798–1806
20. Sarkaria JN et al (2007) Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6(3):1167–1174
21. Hashizume R et al (2010) Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Neurooncology 12(4):366–376
22. Wang J et al (2009) A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 9:465
23. Poulikakos PI et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464(7287):427–430
24. Merten R et al (2014) Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. Strahlentherapie Onkologie 190(12):1169–1172
25. Nicolaides TP et al (2011) Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res 17(24):7595–7604
26. Hidalgo M (2003) Erlotinib: preclinical investigations. Oncology 17(11 Suppl 12):11–16
27. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol 4(2):86–100
28. Hecht M et al (2015) Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26(6):1238–1244
29. Boussemart L et al (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149(7):855–857
30. Peuvrel L et al (2013) Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23(6):879–881
31. Narayana A et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411–416
32. Forschner A et al (2014) Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 24(5):512–516
33. Stein AP et al (2015) Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Med 4(5):699–712
34. Ryu CH et al (2012) Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells. J Biomed Biotechnol 2012:987495